EXCLUSIVE INSIGHT: China To Clarify MRCT Regulatory Pathway Soon
This article was originally published in PharmAsia News
Executive Summary
One year after breaking the story of China starting a review of the widely used multiregional clinical trial pathway, PharmAsia News talks to regulatory affairs insiders to unearth coming changes that will have far-reaching effects on R&D-based drug firms in the country.